Overview

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Status:
Recruiting

Trial end date:
2022-07-30

Target enrollment:

Participant gender:

Summary

The primary objectives of the study are to evaluate the Pharmacokinetics，Safety and tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW117) in patients with severe hemophilia A. The secondary objectives are to monitor anti-durg antibodies and anti-PEG antibodies levels in patients with severe hemophilia A

Phase:

Phase 1

Details

Lead Sponsor:

Jiangsu Gensciences lnc.

Treatments:

Factor VIII